| ZEVRA THERAPEUTICS |
| USA |
| Gesundheit |
| US4884452065 / A2QLX7 |
| 1GDA (Frankfurt) / ZVRA (NASDAQ) |
| FRA:1GDA, ETR:1GDA, 1GDA:GR, NASDAQ:ZVRA |
| - |
| https://zevra.com/ |
|
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that develops and commercializes therapies for diseases with limited or no treatment options, particularly in neurology and sleep disorders. The company focuses on unmet needs in con..
>Volltext.. |
| 478.62 Mio. EUR |
| 369.85 Mio. EUR |
| 92.24 Mio. EUR |
| -0.16 Mio. EUR |
| 71.81 Mio. EUR |
| 1.3 EUR |
| 54.76 Mio. EUR |
| 54.06 Mio. EUR |
| -1.38 Mio. EUR |
| 4.86 |
| 297.44% |
| - |
| - |
| - |
| - |
| - |
| ZEVRA |
| 04.04.26 |
|